Active ingredientValbenazineCat. No. P-V004-001CAS 1025504-45-3Family · Pharmaceutical analytical standards
Valbenazine
An inhibitor of the vesicular transporter VMAT2, which lowers the dopamine available at synapses: approved in the United States in 2017 as the first medicine authorised for tardive dyskinesia, a disorder of involuntary movements. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It is a prodrug: a dihydrotetrabenazine molecule linked to the amino acid L-valine, which the body cleaves off to release the active form.
Go to the active ingredient →Active ingredientValbenazineCat. No. P-V004-001CAS 1025504-45-3
Isotopically labelledValbenazine-d6Cat. No. P-V004-002CAS 1621141-03-4
Impurityent-ValbenazineCat. No. P-V004-003
Impurityent-Valbenazine Di-p-ToluenesulfonateCat. No. P-V004-004
ImpurityValbenazine Impurity 1Cat. No. P-V004-005
ImpurityValbenazine Impurity 2Cat. No. P-V004-006
ImpurityValbenazine N-Oxide (mixture of stereoisomers)Cat. No. P-V004-008No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.